Taysha Gene Therapies Inc. (NASDAQ: TSHA ) is one of the 10 affordable biotech stocks to buy right now .
On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its common stock, priced at $6 per share. The offering also involved prepaid warrants to buy 833,333 shares at $5.999 per warrant.
Pixabay/Public domain
The company anticipates gross proceeds of around $200 million before accounting for underwriting commissions, discounts, and expenses, not including any underwriters' option exercise. The company has granted the underwriters a 30-day option to buy up to an additional 5 million common shares.
On June 23, Bank of America Securities increased its target price on Taysha Gene Therapies Inc. (NASDAQ:TSHA) from $9 to $10, leading to an adjusted upside potential of more than 57%. The firm maintained a Buy rating on the stock following the company's update regarding the Part A REVEAL study to evaluate TSHA-102 in Rett syndrome.
The firm stated the data supports the position of TSHA-102 as the earliest available disease-modifying treatment for Rett syndrome.
Taysha Gene Therapies Inc. (NASDAQ:TSHA) develops gene therapies that are based on adeno-associated virus. Its offerings include therapies such as TSHA-120, TSHA-102, TSHA-105, and others, aimed at the treatment of rare genetic diseases.
While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .
Disclosure: None. Follow Insider Monkey on Google News .
